Overall world revenue for Cell and Gene Therapy Cold Chain Logistics Market, 2024 to 2034 in terms of value the market will surpass US$1,800 million in 2024, the work calculates. The publisher predicts strong revenue growth through to 2034. The work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
The Cell and Gene Therapy Cold Chain Logistics Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
Furthermore, the shortage of trained personnel in cold chain management exacerbates these issues, emphasizing the need for specialized training programs. Collaborations between global organizations like the WHO and local authorities are essential to enhancing cold chain logistics capabilities. Such partnerships can significantly improve the infrastructure needed to support the widespread availability of cell and gene therapies, ultimately expanding access to these critical treatments in underserved regions.
Others
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 23 leading national markets:
The Cell and Gene Therapy Cold Chain Logistics Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
High Cancer Prevalence is Propelling the Adoption of Cell and Gene Therapies
The global incidence of cancer has been rising steadily over the past decade, significantly influencing the adoption of advanced treatments like cell and gene therapies. This increase includes various cancers such as lymphoma, leukemia, myeloma, and melanoma, which affect critical bodily systems including the lymphatic system, lymph nodes, bone marrow, and blood cells. PAHO/WHO reported that in 2023, there were around 20 million new cancer cases. Projections indicate a notable increase in the global cancer burden, with over 28 million new cases expected by 2040. In the U.S., Non-Hodgkin lymphoma alone accounts for more than 4% of all cancer cases, making it one of the most prevalent types. These statistics underscore the urgent need for innovative treatments. Cell and gene therapies, which have shown remarkable success and received regulatory approval, are increasingly seen as vital to addressing the unmet medical needs of cancer patients worldwide.Inadequate Infrastructure for Cold Chain Logistics in Developing Nations Likely to Challenge Industry Growth
Access to cell and gene therapies in developing and remote regions is significantly restricted by inadequate cold chain logistics infrastructure. The reliability of refrigeration is often compromised by inconsistent power supplies, leading to a heightened risk of product spoilage. Transportation infrastructure in these regions also poses a major challenge, complicating the timely delivery of therapies and resulting in delays. Overcoming these logistical barriers requires strategic partnerships with local logistics providers, such as Riders for Health in Africa, to ensure effective distribution networks.Furthermore, the shortage of trained personnel in cold chain management exacerbates these issues, emphasizing the need for specialized training programs. Collaborations between global organizations like the WHO and local authorities are essential to enhancing cold chain logistics capabilities. Such partnerships can significantly improve the infrastructure needed to support the widespread availability of cell and gene therapies, ultimately expanding access to these critical treatments in underserved regions.
Key Questions Answered
- How is the cell and gene therapy cold chain logistics market evolving?
- What is driving and restraining the cell and gene therapy cold chain logistics market?
- How will each cell and gene therapy cold chain logistics submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?
- How will the market shares for each cell and gene therapy cold chain logistics submarket develop from 2024 to 2034?
- What will be the main driver for the overall market from 2024 to 2034?
- Will leading cell and gene therapy cold chain logistics markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
- How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?
- Who are the leading players and what are their prospects over the forecast period?
- What are the cell and gene therapy cold chain logistics projects for these leading companies?
- How will the industry evolve during the period between 2024 and 2034? What are the implications of cell and gene therapy cold chain logistics projects taking place now and over the next 10 years?
- Is there a greater need for product commercialisation to further scale the cell and gene therapy cold chain logistics market?
- Where is the cell and gene therapy cold chain logistics market heading and how can you ensure you are at the forefront of the market?
- What are the best investment options for new product and service lines?
- What are the key prospects for moving companies into a new growth path and C-suite?
You need to discover how this will impact the cell and gene therapy cold chain logistics market today, and over the next 10 years:
- This 359-page report provides 146 tables and 198 charts/graphs exclusively to you.
- The report highlights key lucrative areas in the industry so you can target them - NOW.
- It contains in-depth analysis of global, regional and national sales and growth.
- It highlights for you the key successful trends, changes and revenue projections made by your competitors.
Forecasts to 2034 and other analyses reveal commercial prospects
- In addition to revenue forecasting to 2034, the new study provides you with recent results, growth rates, and market shares.
- You will find original analyses, with business outlooks and developments.
- Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), and recent developments.
Segments Covered in the Report
Component
- Cryogenic Shippers
- Cryogenic Storage Freezers
- Ultra-Low Freezers
- Cold Chain Management Systems
- Shipment and Storage Medium
- Cryogenic Packout Kits
- Others
Services
- Transportation
- Storage
- Packaging
Mode of Transport
- Air Transport
- Ground Transport
- Water Transport
Holding Temperature Range
- Cryogenic
- Refrigerated
- Ambient
- Others
End-users
- Biopharmaceutical and Biotechnology Companies
Others
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 23 leading national markets:
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Switzerland
- Belgium
- Rest of Europe
Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Singapore
- Malaysia
- Thailand
- Rest of Asia Pacific
Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
MEA
- GCC
- South Africa
- Rest of MEA
Leading companies profiled in the report
- A.P. Moller - Maersk
- Arvato SE
- Atelerix Ltd.
- BioLife Solutions Inc.
- BioStor Sytems Inc.
- Cardinal Health
- Catalent Inc.
- Cencora, Inc.
- CryoPort Inc.
- DHL
- FedEx
- Marken (a UPS Company)
- MasterControl Solutions, Inc.
- Modality Solutions
- NMDP BioTherapies
- Nordic Cold Chain Solutions
- sedApta s.r.l.
- Polar Express Transportation
- Thermo Fisher Scientific Inc.
- TrakCel
- Yourway
How will the Cell and Gene Therapy Cold Chain Logistics Market, 2024 to 2034 report help you?
In summary, the 350+ page report provides you with the following knowledge:- Revenue forecasts to 2034 for Cell and Gene Therapy Cold Chain Logistics Market, 2024 to 2034, with forecasts for component, services, mode of transport, holding temperature range, and end-user, each forecast at a global and regional level - discover the industry’s prospects, finding the most lucrative places for investments and revenues.
- Revenue forecasts to 2034 for five regional and 23 key national markets - See forecasts for the Cell and Gene Therapy Cold Chain Logistics Market, 2024 to 2034 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the U.S., Canada, Germany, UK, France, Italy, Spain, Russia, Switzerland, Belgium, Japan, China, India, Australia, South Korea, Singapore, Malaysia, Thailand, Brazil, Mexico, Argentina, GCC, and South Africa among other prominent economies.
- Prospects for established firms and those seeking to enter the market - including company profiles for 21 of the major companies involved in the Cell and Gene Therapy Cold Chain Logistics Market, 2024 to 2034.
Information found nowhere else
With this new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how this work could benefit your research, analyses, and decisions. This study is for everybody needing commercial analyses for the Cell and Gene Therapy Cold Chain Logistics Market, 2024 to 2034, market-leading companies. You will find data, trends and predictions.Table of Contents
1 Report Overview
3 Market Overview
4 Cell and Gene Therapy Cold Chain Logistics Market Analysis by Components
5 Cell and Gene Therapy Cold Chain Logistics Market Analysis by Services
6 Cell and Gene Therapy Cold Chain Logistics Market Analysis by Mode of Transport
7 Cell and Gene Therapy Cold Chain Logistics Market Analysis by Holding Temperature
8 Cell and Gene Therapy Cold Chain Logistics Market Analysis by End-users
9 Cell and Gene Therapy Cold Chain Logistics Market Analysis by Region
10 North America Cell and Gene Therapy Cold Chain Logistics Market Analysis
11 Europe Cell and Gene Therapy Cold Chain Logistics Market Analysis
12 Asia Cell and Gene Therapy Cold Chain Logistics Market Analysis
13 Latin America Cell and Gene Therapy Cold Chain Logistics Market Analysis
14 MEA Cell and Gene Therapy Cold Chain Logistics Market Analysis
15 Company Profiles
16 Conclusion and Recommendations
List of Tables
List of Figures
Companies Mentioned
- A.P. Moller – Maersk
- Arvato SE
- Atelerix Ltd.
- BioLife Solutions Inc.
- BioStor Sytems Inc.
- Cardinal Health
- Catalent Inc.
- Cencora, Inc.
- CryoPort Inc.
- DHL
- FedEx
- Marken (a UPS Company)
- MasterControl Solutions, Inc.
- Modality Solutions
- NMDP BioTherapies
- Nordic Cold Chain Solutions
- Polar Express Transportation
- sedApta s.r.l.
- Thermo Fisher Scientific Inc.
- TrakCel
- Yourway
- AbbVie
- AbelZeta Pharma Inc.
- Acino
- AD Ports Logistics (ADPL)
- Almac Clinical Services
- AmerisourceBergen's World Courier
- AstraZeneca
- Autolus Therapeutics plc
- Avery Dennison
- Bayer AG
- BioNTech SE
- BioVex, Inc. (Amgen Inc.)
- Bluebird bio
- Bristol Myers Squibb
- Cartherics Pty Ltd
- Cavalier International Air Freight, Inc.
- Cavalier Logistics Management II, Inc.
- Celgene Corporation
- Cell and Gene Therapy Catapult
- Cellares
- Cellbox Solutions GmbH
- Cellectis
- CellResearch Corporation
- Central Pharma
- Cleveland Cord Blood Center
- CRISPR Therapeutics
- CryoPDP
- Csafe
- CSL Behring LLC, UniQure
- CSPC Pharmaceutical Group Limited (CSPC)
- Cyto-Facto
- DB Schenker
- DC Dyna, Inc.
- Decibel Therapeutics, Inc.
- Enzyvant Therapeutics GmbH
- Exeltainer
- Ferring Pharmaceuticals A/S
- Fresenius Kabi
- Hanjin
- Hovione
- iBET
- Immunoadoptive Cell Therapy Private Ltd (ImmunoACT)
- Iovance Biotherapeutics
- Itransition
- Janssen Biotech, Inc.
- Juno Therapeutics, Inc.
- Kite Pharma, Inc.
- Krystal Biotech
- Kymriah
- Laurus Labs
- Legend Biotech
- LifeX Ventures
- Limula
- Long Feng Medical Logistics
- Lupagen Inc.
- Miltenyi Biotec
- Mitsubishi Logistics Corporation (Japan)
- National Resilience Inc.
- NIPPON EXPRESS
- Novartis Gene Therapies, Inc.
- Novartis Pharmaceuticals Corporation
- Novena Global Lifecare
- Orchard Therapeutics
- Pelican BioThermal
- Pfizer
- PharmaLex Holding GmbH
- Pharmaniaga Berhad (Pharmaniaga)
- Porton Advanced Solutions
- Prologis
- ProPharma
- Regeneron Pharmaceuticals, Inc.
- Roche
- Roland Berger
- Sanofi
- Sarepta Therapeutics, Inc.
- Sartorius
- Saudi Cargo, the cargo division of Saudi Arabian Airlines
- SCG Cell Therapy
- Scintila S.R.O
- Sensitech
- SkyCell
- Spark Therapeutics, Inc.
- Stratatech Corporation
- Sure Chill
- Syneos Health
- Taikoo Motors
- Tec4med Lifescience GmbH
- TEIJIN CDMO
- TICAROS
- TiCARos Co Ltd.
- Tower Cold Chain
- TreeFrog Therapeutics
- Umoja Biopharma
- UPS Healthcare
- va-Q-tec
- Vertex
- VGXI Inc.
- ViSync Technologies
- Vitesco Technologies
- World Courier
- WuXi Advanced Therapies (WuXi ATU)
- Yinjia (Shanghai) Biosciences
- Zuellig Pharma
- Zühlke Ventures
- American Cancer Society
- American Society of Clinical Oncology
- Argentina government
- Argentina: National Administration on Drugs, Foods, and Medical Devices (ANMAT)
- Argentine Network of Tissue Banks (RATI)
- Berlin Institute of Health
- Centers for Medicare and Medicaid Services
- European Commission
- Federal Government, Australia
- Genethon, Institut Imagine, France
- IATA Temperature Control Regulations (TCR)
- Independent Validators (CEIV)
- International Air Transport Association (IATA)
- International Maritime Dangerous Goods (IMDG)
- Korean Ministry of Food and Drug Safety (MFDS)
- Ministry of Health, Argentina
- National Research Council
- National Center for Biotechnology Information (NCBI)
- Pan American Health Organization (PAHO)
- U.S. Food and Drug Administration (FDA)
- World Health Organization (WHO)